Company profile ACAD

Acadia Pharmaceuticals Inc
acadia pharmaceuticals (nasdaq: acad) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (cns) disorders. all of acadia's product candidates emanate from internal discoveries. we believe that they offer innovative therapeutic approaches that may provide signif...icant advantages relative to current therapies. acadia’s history is rooted in science and strong leadership in cns research. our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. acadia is headquartered in san diego. the city represents the second largest biotechnology industry cluster in the united states, home to over 400 companies, as well as the salk institute for biological studies Show More
Quarter analysis & expected interestLast update: February 08 2024 12:48:25.

After 39 days of this quarter the interest is at 43.0. Based on that we can calculate that during remaining 52 days it will total up to 100.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019105
124
18.1% QoQ
195
57.3% QoQ
223
14.4% QoQ
2020 197
87.6% YoY -11.7% QoQ
201
62.1% YoY 2.0% QoQ
303
55.4% YoY 50.7% QoQ
254
13.9% YoY -16.2% QoQ
2021 367
86.3% YoY 44.5% QoQ
218
8.5% YoY -40.6% QoQ
138
-54.5% YoY -36.7% QoQ
128
-49.6% YoY -7.2% QoQ
2022 159
-56.7% YoY 24.2% QoQ
159
-27.1% YoY 0.0% QoQ
124
-10.1% YoY -22.0% QoQ
103
-19.5% YoY -16.9% QoQ
2023 154
-3.1% YoY 49.5% QoQ
140
-11.9% YoY -9.1% QoQ
121
-2.4% YoY -13.6% QoQ
121
17.5% YoY 0.0% QoQ
2024 43
-72.1% YoY -64.5% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and ACADIA Pharmaceuticals search interestLast update: February 08 2024 12:48:24.
Correlation coefficient between keyword and revenue is -0.1
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 12:48:26.

The average 5 years interest of ACADIA Pharmaceuticals was 13.7 per week.
The last year interest of ACADIA Pharmaceuticals compared to the last 5 years has changed by -26.72%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -28.69%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ACADIA Pharmaceuticals NUPLAZID to provide analysis

Correlation between past revenue and ACADIA Pharmaceuticals NUPLAZID search interest

There is not enough data for ACADIA Pharmaceuticals NUPLAZID to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ACADIA Pharmaceuticals NUPLAZID to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ACADIA Pharmaceuticals Parkinson's treatment to provide analysis

Correlation between past revenue and ACADIA Pharmaceuticals Parkinson's treatment search interest

There is not enough data for ACADIA Pharmaceuticals Parkinson's treatment to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ACADIA Pharmaceuticals Parkinson's treatment to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ACADIA Pharmaceuticals CNS disorders to provide analysis

Correlation between past revenue and ACADIA Pharmaceuticals CNS disorders search interest

There is not enough data for ACADIA Pharmaceuticals CNS disorders to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ACADIA Pharmaceuticals CNS disorders to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ACADIA Pharmaceuticals rare diseases to provide analysis

Correlation between past revenue and ACADIA Pharmaceuticals rare diseases search interest

There is not enough data for ACADIA Pharmaceuticals rare diseases to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ACADIA Pharmaceuticals rare diseases to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ACADIA Pharmaceuticals Phase III study to provide analysis

Correlation between past revenue and ACADIA Pharmaceuticals Phase III study search interest

There is not enough data for ACADIA Pharmaceuticals Phase III study to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ACADIA Pharmaceuticals Phase III study to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 12:48:31.

After 39 days of this quarter the interest is at 24.0. Based on that we can calculate that during remaining 52 days it will total up to 56.0.
ACADIA Pharmaceuticals careers expected interest is significantly lower compared to previous quarter (-63.6%) and same quarter last year (-56.2%).

YearQ1Q2Q3Q4
2019110
230
109.1% QoQ
60
-73.9% QoQ
131
118.3% QoQ
2020 108
-1.8% YoY -17.6% QoQ
102
-55.7% YoY -5.6% QoQ
50
-16.7% YoY -51.0% QoQ
232
77.1% YoY 364.0% QoQ
2021 184
70.4% YoY -20.7% QoQ
49
-52.0% YoY -73.4% QoQ
23
-54.0% YoY -53.1% QoQ
66
-71.6% YoY 187.0% QoQ
2022 22
-88.0% YoY -66.7% QoQ
0
-100.0% YoY -100.0% QoQ
30
30.4% YoY inf% QoQ
224
239.4% YoY 646.7% QoQ
2023 128
481.8% YoY -42.9% QoQ
153
inf% YoY 19.5% QoQ
50
66.7% YoY -67.3% QoQ
154
-31.2% YoY 208.0% QoQ
2024 24
-81.2% YoY -84.4% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and ACADIA Pharmaceuticals careers search interestLast update: February 08 2024 12:48:30.
Correlation coefficient between keyword and revenue is -0.14
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 12:48:32.

The average 5 years interest of ACADIA Pharmaceuticals careers was 8.16 per week.
The last year interest of ACADIA Pharmaceuticals careers compared to the last 5 years has changed by 12.62%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -21.52%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for ACADIA Pharmaceuticals review to provide analysis

Correlation between past revenue and ACADIA Pharmaceuticals review search interest

There is not enough data for ACADIA Pharmaceuticals review to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for ACADIA Pharmaceuticals review to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: November 03 2023 04:22:38.

After 34 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 58 days it will total up to 0.0.
ACADIA Pharmaceuticals news expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).

YearQ1Q2Q3Q4
2018 - - - 0
2019 0
0
0
0
2020 0
0
308
inf% YoY inf% QoQ
215
inf% YoY -30.2% QoQ
2021 171
inf% YoY -20.5% QoQ
128
inf% YoY -25.1% QoQ
64
-79.2% YoY -50.0% QoQ
88
-59.1% YoY 37.5% QoQ
2022 100
-41.5% YoY 13.6% QoQ
125
-2.3% YoY 25.0% QoQ
180
181.2% YoY 44.0% QoQ
122
38.6% YoY -32.2% QoQ
2023 91
-9.0% YoY -25.4% QoQ
154
23.2% YoY 69.2% QoQ
124
-31.1% YoY -19.5% QoQ
0
-100.0% YoY -100.0% QoQ
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and ACADIA Pharmaceuticals news search interestLast update: November 03 2023 04:22:38.
Correlation coefficient between keyword and revenue is 0.61
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: November 03 2023 04:22:38.

The average 5 years interest of ACADIA Pharmaceuticals news was 7.16 per week.
The last year interest of ACADIA Pharmaceuticals news compared to the last 5 years has changed by 17.6%.
This is something to be checked.
This didn't exist 5 years ago.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 12:48:37.

After 39 days of this quarter the interest is at 33.0. Based on that we can calculate that during remaining 52 days it will total up to 77.0.
ACADIA Pharmaceuticals -stock -company expected interest is significantly lower compared to same quarter last year (-56.7%) but similar to previous quarter.

YearQ1Q2Q3Q4
2019107
157
46.7% QoQ
284
80.9% QoQ
218
-23.2% QoQ
2020 210
96.3% YoY -3.7% QoQ
211
34.4% YoY 0.5% QoQ
294
3.5% YoY 39.3% QoQ
200
-8.3% YoY -32.0% QoQ
2021 315
50.0% YoY 57.5% QoQ
180
-14.7% YoY -42.9% QoQ
140
-52.4% YoY -22.2% QoQ
148
-26.0% YoY 5.7% QoQ
2022 163
-48.3% YoY 10.1% QoQ
205
13.9% YoY 25.8% QoQ
196
40.0% YoY -4.4% QoQ
150
1.4% YoY -23.5% QoQ
2023 178
9.2% YoY 18.7% QoQ
183
-10.7% YoY 2.8% QoQ
138
-29.6% YoY -24.6% QoQ
122
-18.7% YoY -11.6% QoQ
2024 33
-81.5% YoY -73.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and ACADIA Pharmaceuticals -stock -company search interestLast update: February 08 2024 12:48:37.
Correlation coefficient between keyword and revenue is -0.02
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 12:48:39.

The average 5 years interest of ACADIA Pharmaceuticals -stock -company was 14.68 per week.
The last year interest of ACADIA Pharmaceuticals -stock -company compared to the last 5 years has changed by -23.37%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -30.21%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for ACAD
Earnings date: 2024-02-26 After close
Company name: Acadia Pharmaceuticals Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-08T20:43:19Z

Analyst Upgrades
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $32

2026-05-06T20:05:00Z

BusinessWire
Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

2026-04-30T20:05:00Z

BusinessWire
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career

2026-04-28T20:05:00Z

BusinessWire
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

2026-04-17T13:05:00Z

BusinessWire
Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting

2026-04-15T20:05:00Z

BusinessWire
Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

2026-04-07T13:05:00Z

BusinessWire
Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome

2026-03-25T19:43:47Z

Analyst Upgrades
This General Motors Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

2026-03-25T12:46:08Z

Analyst Upgrades
B of A Securities Upgrades ACADIA Pharmaceuticals to Buy, Maintains Price Target to $29

2026-03-12T20:05:00Z

BusinessWire
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

2026-03-04T20:33:26Z

Analyst Upgrades
JP Morgan Maintains Overweight on ACADIA Pharmaceuticals, Raises Price Target to $34

2026-03-03T21:05:00Z

BusinessWire
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors

2026-03-02T21:05:00Z

BusinessWire
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome

2026-02-26T17:38:01Z

Analyst Upgrades
TD Cowen Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $37

2026-02-26T15:30:06Z

Analyst Upgrades
RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $30